Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
Authors: Dudley J. Pennell
John B. Porter
Maria Domenica Cappellini
Lee Lee Chan
Amal El-Beshlawy
Yesim Aydinok
Hishamshah Ibrahim
Chi Kong Li
Vip Viprakasit
Mohsen Saleh Elalfy
Antonis Kattamis
Gillian Smith
Dany Habr
Gabor Domokos
Bernard Roubert
Ali Taher
Royal Brompton Hospital
Universita degli Studi di Milano
University of Malaya Medical Centre
Cairo University
Ege University Medical School
Kuala Lumpur Hospital
Prince of Wales Hospital Hong Kong
Mahidol University
Ain Shams University
University of Athens
Novartis Pharmaceuticals
Novartis International AG
American University of Beirut
Keywords: Medicine
Issue Date: 1-Jan-2011
Citation: Haematologica. Vol.96, No.1 (2011), 48-54
Abstract: Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe ( > 5 to < 10 ms) in 39 patients, and moderate-to-mild (10 to < 20 ms) in 62 patients. Mean deferasirox dose was 33.1±3.7 mg/kg/d in the one-year core study increasing to 36.1±7.7 mg/kg/d during the second year of treatment. Geometric mean myocardial T2* increased from a baseline of 11.2 to 14.8 ms at two years (P < 0.001). In patients with moderate-to-mild baseline T2*, an increase was seen from 14.7 to 20.1 ms, with normalization (≥20 ms) in 56.7% of patients. In those with severe cardiac iron overload at baseline, 42.9% improved to the moderate-to-mild group. The incidence of drug-related adverse events did not increase during the extension relative to the core study and included (≥5%) increased serum creatinine, rash and increased alanine aminotransferase. Conclusions Continuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d continued to remove iron from the heart in patients with β-thalassemia major and mild, moderate and severe cardiac siderosis. © 2011 Ferrata Storti Foundation.
ISSN: 15928721
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.